These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 7466740)
1. Evaluation of the effect of betapropiolactone/ultraviolet irradiation (BPL/UV) treatment of source plasma on hepatitis transmission by factor IX complex in chimpanzees. Prince AM; Stephan W; Brotman B; van den Ende MC Thromb Haemost; 1980 Dec; 44(3):138-42. PubMed ID: 7466740 [TBL] [Abstract][Full Text] [Related]
2. Inactivation of hepatitis B and non-A, non-B viruses by combined use of Tween 80, beta-propiolactone, and ultraviolet irradiation. Prince AM; Stephan W; Kotitschke R; Brotman B Thromb Haemost; 1983 Aug; 50(2):534-6. PubMed ID: 6415846 [TBL] [Abstract][Full Text] [Related]
3. Long-term tolerance and recovery of beta-propiolactone/ultraviolet (beta PL/UV) treated PPSB in chimpanzees. Stephan W; Kotitschke R; Prince AM; Brotman B Thromb Haemost; 1981 Aug; 46(2):511-4. PubMed ID: 7302890 [TBL] [Abstract][Full Text] [Related]
4. Factor VIII concentrate from cold sterilized human plasma. Stephan W; Prince AM; Kotitschke R Dev Biol Stand; 1983; 54():491-5. PubMed ID: 6418593 [TBL] [Abstract][Full Text] [Related]
5. Virus safety of beta-propiolactone treated plasma preparations. Clinical experiences. Heinrich D; Sugg U; Brackmann HH; Stephan W; Lissner R Dev Biol Stand; 1987; 67():311-7. PubMed ID: 3649316 [TBL] [Abstract][Full Text] [Related]
6. Inactivation of non-A, non-B virus infectivity by a beta propiolactone/ultraviolet irradiation treatment and Aerosil adsorption procedure used for preparation of a stabilized human serum. Prince AM; Stephan W; Brotman B Vox Sang; 1984; 46(2):80-5. PubMed ID: 6322448 [TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of the hepatitis safety of a beta-propiolactone/ultraviolet treated factor IX concentrate (PPSB). Heinrich D; Kotitschke R; Berthold H Thromb Res; 1982 Oct; 28(1):75-83. PubMed ID: 7157232 [TBL] [Abstract][Full Text] [Related]
8. beta-propiolactone/ultraviolet irradiation: a review of its effectiveness for inactivation of viruses in blood derivatives. Prince AM; Stephan W; Brotman B Rev Infect Dis; 1983; 5(1):92-107. PubMed ID: 6828813 [TBL] [Abstract][Full Text] [Related]
9. Effect of combined treatment of serum containing hepatitis B virus with beta-propiolactone and ultraviolet irradiation. Stephan W; Berthold H; Prince AM Vox Sang; 1981 Sep; 41(3):134-8. PubMed ID: 7331286 [TBL] [Abstract][Full Text] [Related]
10. Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate. Prince AM; Horowitz B; Brotman B Lancet; 1986 Mar; 1(8483):706-10. PubMed ID: 2870224 [TBL] [Abstract][Full Text] [Related]
11. Beta-propiolactone for the inactivation of non-A/non-B type 1 hepatitis virus capable of inducing cytoplasmic tubular ultrastructures in chimpanzees. Yoshizawa H; Itoh Y; Iwakiri S; Kitajima K; Noguchi Y; Tachibana K; Nakamura T; Miyakawa Y; Mayumi M Vox Sang; 1984; 46(2):86-91. PubMed ID: 6422638 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of thrombogenicity of beta-propiolactone/ultraviolet (beta-PL/UV) treated PPSB in chimpanzees. Kotitschke R; Stephan W; Prince AM; Brotman B Thromb Res; 1983 May; 30(3):235-44. PubMed ID: 6868023 [TBL] [Abstract][Full Text] [Related]
13. Titration of hepatitis B virus infectivity in the sera of pre-acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes. Tabuchi A; Tanaka J; Katayama K; Mizui M; Matsukura H; Yugi H; Shimada T; Miyakawa Y; Yoshizawa H J Med Virol; 2008 Dec; 80(12):2064-8. PubMed ID: 19040280 [TBL] [Abstract][Full Text] [Related]
14. Inactivation of the Hutchinson strain of non-A, non-B hepatitis virus by combined use of beta-propiolactone and ultraviolet irradiation. Prince AM; Stephan W; Dichtelmüller H; Brotman B; Huima T J Med Virol; 1985 Jun; 16(2):119-25. PubMed ID: 3925077 [TBL] [Abstract][Full Text] [Related]
15. Removal of hepatitis-B-virus infectivity from factor-IX complex by hepatitis-B immune-globulin. Experiments in chimpanzees. Tabor E; Aronson DL; Gerety RJ Lancet; 1980 Jul; 2(8185):68-70. PubMed ID: 6105247 [TBL] [Abstract][Full Text] [Related]
16. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety. Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288 [TBL] [Abstract][Full Text] [Related]
17. Current safety of clotting factor concentrates. Epstein JS; Fricke WA Arch Pathol Lab Med; 1990 Mar; 114(3):335-40. PubMed ID: 2407224 [TBL] [Abstract][Full Text] [Related]
18. Inactivation of HTLV-III/LAV, hepatitis B and non-A/non-B viruses by pasteurization in human plasma protein preparations. Mauler R; Merkle W; Hilfenhaus J Dev Biol Stand; 1987; 67():337-51. PubMed ID: 3111911 [TBL] [Abstract][Full Text] [Related]
19. Neutralization of hepatitis B virus (HBV) by human monoclonal antibody against HBV surface antigen (HBsAg) in chimpanzees. Kim SH; Shin YW; Hong KW; Chang KH; Ryoo KH; Paik SH; Kim JM; Brotman B; Pfahler W; Prince AM Antiviral Res; 2008 Sep; 79(3):188-91. PubMed ID: 18479762 [TBL] [Abstract][Full Text] [Related]
20. Fractionation of cold-sterilized plasma. A new concept in production of non-infectious plasma proteins. Stephan W Arzneimittelforschung; 1982; 32(8):799-801. PubMed ID: 6890353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]